Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?
Search for other papers by Shaji K. Kumar in
Current site
Google Scholar
PubMed
Although recent advances in the treatment of multiple myeloma have improved survival, it remains a chronic disease that requires a long-term treatment strategy. The key to achieving the best outcomes for patients is delivering the best “package” of treatment at a given stage. This means using optimal combinations that maximize benefit based on what patients have received previously and minimize treatment-related toxicity. Sequencing of regimens also plays an important role. As new agents and new classes of drugs continue to be approved for multiple myeloma, future strategies will use more individualized approaches to treatment.
Disclosures: Dr. Kumar has disclosed that he has received honoraria from BeiGene; grant/research support from AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Janssen Pharmaceutica Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Roche Laboratories, Inc., sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., TeneBio; and consulting fees from Cellectar Biosciences, GeneCentrix, Inc, Oncopeptides. He is also a scientific advisor for AbbVie, Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceutica Products, LP, MedImmune Inc., and sanofi-aventis U.S.
© 2019-2024 National Comprehensive Cancer Network